KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension.

Nichola Cooper, James B Bussel, Maciej Kaźmierczak, Yoshitaka Miyakawa, Sarah Cluck, Rocío Lledó García, Birgit Haier, Andreea Lavrov, Puneet Singh, Rose Snipes, David J Kuter

Br J Haematol 206(2) 675-688

PMID39552477
PMCIDPMC11829145
DOI10.1111/bjh.19858
发表日期2024-11-18
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Primary immune thrombocytopenia (ITP) is an antiplatelet-antibody-mediated disorder with accelerated platelet clearance and decreased platelet production. Rozanolixizumab, a monoclonal IgG4 anti-FcRn antibody, blocks IgG recycling and decreases IgG levels. We report efficacy and safety of rozanolixizumab in adults with persistent/chronic ITP in 24-week phase 3 studies (TP0003; TP0006), and their 52-week open-label extension (OLE). Primary end-point was durable clinically meaningful platelet response (DCMPR) of ≥50 × 109/L for 8/12 weeks during Weeks 13-25 in the double-blind studies. Operational delays and evolving ITP treatment landscape led the sponsor to terminate these studies early; thus, only 21 and 12 (TP0003) and 20 and 10 (TP0006) patients were randomised to rozanolixizumab or placebo. Forty-three patients enrolled in the OLE: 42 started on every 2-week dosing; 21 later switched to weekly dosing. More rozanolixizumab-treated than placebo-treated patients achieved DCMPR: 4/21 versus 0 (TP0003) and 1/20 versus 0 (TP0006). Platelet increases to ≥50 × 109/L were observed on Day 8 in 52.4% (TP0003; 2/12 placebo) and 45.0% (TP0006; 1/10 placebo) of rozanolixizumab-treated patients. OLE platelet increases were maintained while on weekly dosing. The most frequent treatment-emergent adverse events overall were headache, pyrexia and nausea, as seen previously. Weekly dosing appears more efficacious than every 2-week dosing.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。